

# Seok Jin Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3724984/publications.pdf>

Version: 2024-02-01

355  
papers

8,403  
citations

71102

41  
h-index

76900

74  
g-index

373  
all docs

373  
docs citations

373  
times ranked

9722  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. <i>Blood</i> , 2017, 129, 2437-2442.	1.4	399
2	SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. <i>Blood</i> , 2012, 120, 2973-2980.	1.4	361
3	A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 371-375.	21.4	326
4	Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6027-6032.	1.6	312
5	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
6	Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. <i>Genome Research</i> , 2018, 28, 1217-1227.	5.5	172
7	Expression of HIF-1 $\alpha$ , CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 325-335.	2.0	159
8	Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2103-2109.	1.6	149
9	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. <i>Oncotarget</i> , 2015, 6, 17764-17776.	1.8	136
10	Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. <i>American Journal of Hematology</i> , 2012, 87, 663-668.	4.1	134
11	Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. <i>Blood</i> , 2011, 117, 1958-1965.	1.4	121
12	Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. <i>Annals of Hematology</i> , 2014, 93, 1895-1901.	1.8	115
13	Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). <i>BMC Cancer</i> , 2011, 11, 321.	2.6	107
14	Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. <i>European Journal of Cancer</i> , 2013, 49, 3486-3496.	2.8	103
15	Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. <i>European Journal of Cancer</i> , 2012, 48, 3223-3231.	2.8	99
16	Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. <i>Haematologica</i> , 2010, 95, 1935-1942.	3.5	95
17	Carbonic Anhydrase IX in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7925-7933.	7.0	87
18	Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. <i>Lancet Haematology</i> , the, 2015, 2, e66-e74.	4.6	85

#	ARTICLE	IF	CITATIONS
19	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	4.6	78
20	Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 496.	1.7	77
21	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
22	Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. <i>Haematologica</i> , 2016, 101, 757-763.	3.5	75
23	Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. <i>Blood</i> , 2020, 136, 2754-2763.	1.4	74
24	Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. <i>BMC Cancer</i> , 2010, 10, 321.	2.6	73
25	Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group. <i>Journal of Hematology and Oncology</i> , 2013, 6, 86.	17.0	67
26	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 757-763.	1.3	63
27	Enteropathy-associated T-cell lymphoma—a clinicopathologic and array comparative genomic hybridization study. <i>Human Pathology</i> , 2010, 41, 1231-1237.	2.0	60
28	Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 237-240.	1.4	59
29	Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. <i>Annals of Hematology</i> , 2015, 94, 71-78.	1.8	58
30	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in <i>TNFAIP3</i> followed by mutations in <i>TBL1XR1</i> and <i>CREBBP</i> . <i>Oncotarget</i> , 2017, 8, 17038-17049.	1.8	55
31	Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Annals of Hematology</i> , 2010, 89, 563-568.	1.8	54
32	Serum Vascular Endothelial Growth Factor per Platelet Count in Hepatocellular Carcinoma: Correlations with Clinical Parameters and Survival. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 184-190.	1.3	53
33	Prognostic Value of Carbonic Anhydrase IX and Ki-67 Expression in Squamous Cell Carcinoma of the Tongue. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 812-819.	1.3	53
34	Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. <i>Investigational New Drugs</i> , 2013, 31, 469-472.	2.6	51
35	Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion. <i>Clinical Cancer Research</i> , 2020, 26, 935-944.	7.0	51
36	Treatment of localized extranodal NK/T cell lymphoma, nasal type. <i>International Journal of Hematology</i> , 2010, 92, 690-696.	1.6	50

#	ARTICLE	IF	CITATIONS
37	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Annals of Hematology</i> , 2012, 91, 543-551.	1.8	50
38	Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. <i>Annals of Hematology</i> , 2011, 90, 1391-1398.	1.8	49
39	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. <i>Lancet Oncology</i> , The, 2020, 21, 306-316.	10.7	49
40	Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population. <i>Thrombosis Research</i> , 2012, 130, e6-e12.	1.7	48
41	Matchedâ€pair analysis comparing the outcomes of primary breast and nodal diffuse large Bâ€cell lymphoma in patients treated with rituximab plus chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, 235-243.	5.1	47
42	Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. <i>Nutrition and Cancer</i> , 2014, 66, 225-233.	2.0	47
43	A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. <i>Haematologica</i> , 2015, 100, e505-e507.	3.5	43
44	Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 140.	17.0	43
45	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2541-2550.	1.8	43
46	Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. <i>Leukemia and Lymphoma</i> , 2006, 47, 1265-1273.	1.3	42
47	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , 2020, 34, 3413-3419.	7.2	42
48	The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 937-940.	4.1	40
49	Isolation of Small Extracellular Vesicles From Human Serum Using a Combination of Ultracentrifugation With Polymer-Based Precipitation. <i>Annals of Laboratory Medicine</i> , 2020, 40, 253-258.	2.5	40
50	Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. <i>Quality of Life Research</i> , 2010, 19, 1097-1103.	3.1	39
51	Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. <i>Journal of Hematology and Oncology</i> , 2011, 4, 34.	17.0	37
52	CD79B limits response of diffuse large B cell lymphoma to ibrutinib. <i>Leukemia and Lymphoma</i> , 2016, 57, 1413-1422.	1.3	37
53	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	37
54	<sup>18</sup>Fâ€FDG uptake and its clinical relevance in primary gastric lymphoma. <i>Hematological Oncology</i> , 2010, 28, 57-61.	1.7	36

#	ARTICLE	IF	CITATIONS
55	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2016, 95, 325-335.	1.8	36
56	Brentuximab vedotin: clinical updates and practical guidance. <i>Blood Research</i> , 2017, 52, 243.	1.3	36
57	Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). <i>Oncotarget</i> , 2016, 7, 85584-85591.	1.8	36
58	Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. <i>American Journal of Hematology</i> , 2003, 73, 263-266.	4.1	35
59	Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas. <i>Acta Haematologica</i> , 2008, 120, 211-216.	1.4	35
60	Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 98, 346-354.	1.6	35
61	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2016, 73, 496-505.	3.3	34
62	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. <i>Modern Pathology</i> , 2020, 33, 603-615.	5.5	34
63	The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2015, 8, 49.	17.0	33
64	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. <i>Oncotarget</i> , 2016, 7, 76934-76943.	1.8	33
65	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. <i>Modern Pathology</i> , 2018, 31, 1418-1428.	5.5	33
66	Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. <i>Leukemia and Lymphoma</i> , 2012, 53, 1515-1524.	1.3	32
67	Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness. <i>Mayo Clinic Proceedings</i> , 2014, 89, 781-789.	3.0	31
68	Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. <i>European Journal of Haematology</i> , 2008, 81, 177-184.	2.2	30
69	Prognostic Significance of Serum Vascular Endothelial Growth Factor Per Platelet Count in Unresectable Advanced Gastric Cancer Patients. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 1147-1153.	1.3	30
70	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1020-1026.	1.3	30
71	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
72	Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. <i>Cancer Medicine</i> , 2019, 8, 4626-4632.	2.8	29

#	ARTICLE	IF	CITATIONS
73	Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism. <i>Cancer Research and Treatment</i> , 2016, 48, 312-321.	3.0	29
74	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. <i>Molecular Therapy</i> , 2022, 30, 579-592.	8.2	29
75	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	1.4	28
76	Rituximab-induced acute thrombocytopenia: a case report and review of the literature. <i>Medical Oncology</i> , 2009, 26, 45-48.	2.5	28
77	Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 353-357.	1.3	28
78	Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 677-683.	0.8	28
79	l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 41.	17.0	28
80	Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2020, 20, 120.	2.6	27
81	Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. <i>Annals of Hematology</i> , 2011, 90, 539-546.	1.8	26
82	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 374-387.	3.0	26
83	Human Placenta-Derived Feeders Support Prolonged Undifferentiated Propagation of a Human Embryonic Stem Cell Line, SNUhES3: Comparison with Human Bone Marrow-Derived Feeders. <i>Stem Cells and Development</i> , 2007, 16, 421-428.	2.1	25
84	Imaging Findings and Literature Review of 18F-FDG PET/CT in Primary Systemic AL Amyloidosis. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 182-190.	1.0	25
85	The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. <i>Leukemia Research</i> , 2010, 34, 294-300.	0.8	24
86	Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. <i>Leukemia Research</i> , 2010, 34, 1175-1179.	0.8	24
87	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613.	2.6	24
88	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
89	A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. <i>Annals of Hematology</i> , 2020, 99, 2095-2104.	1.8	24
90	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2014, 131, 193-199.	1.4	23

#	ARTICLE	IF	CITATIONS
91	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. <i>Oncotarget</i> , 2015, 6, 42803-42812.	1.8	23
92	Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 480-486.	1.7	23
93	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. <i>Respiratory Medicine</i> , 2020, 161, 105853.	2.9	23
94	Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 76231-76240.	1.8	23
95	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. <i>International Journal of Hematology</i> , 2010, 91, 456-463.	1.6	22
96	Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. <i>Leukemia and Lymphoma</i> , 2019, 60, 2237-2246.	1.3	22
97	Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF- $\kappa$ B and Btk. <i>Oncotarget</i> , 2017, 8, 5361-5370.	1.8	22
98	Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. <i>Annals of Hematology</i> , 2009, 88, 1099-1106.	1.8	21
99	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. <i>Leukemia and Lymphoma</i> , 2009, 50, 1119-1125.	1.3	21
100	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 383-388.	1.6	21
101	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , 2013, 14, e548-e561.	10.7	21
102	Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 261-266.	3.0	21
103	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
104	Impact of fear of cancer recurrence on survival among lymphoma patients. <i>Psycho-Oncology</i> , 2020, 29, 364-372.	2.3	21
105	Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. <i>Experimental Hematology and Oncology</i> , 2021, 10, 33.	5.0	21
106	FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 2466-2476.	1.8	21
107	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. <i>Nutrition</i> , 2017, 36, 67-71.	2.4	20
108	PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. <i>Scientific Reports</i> , 2020, 10, 12641.	3.3	20



#	ARTICLE	IF	CITATIONS
109	Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1051-1063.	3.0	20
110	Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 436-442.	2.3	19
111	B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 19-25.	1.3	19
112	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. <i>Annals of Hematology</i> , 2014, 93, 437-447.	1.8	19
113	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly. <i>Current Opinion in Oncology</i> , 2015, 27, 392-398.	2.4	19
114	The t(11;14)(q13;q32) Translocation as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 227-235.	0.4	19
115	Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma. <i>Cancer Research and Treatment</i> , 2018, 50, 575-581.	3.0	19
116	The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker. <i>Anticancer Research</i> , 2018, 38, 3935-3942.	1.1	19
117	Hematopoietic Differentiation of Embryoid Bodies Derived from the Human Embryonic Stem Cell Line SNUhES3 in Co-culture with Human Bone Marrow Stromal Cells. <i>Yonsei Medical Journal</i> , 2005, 46, 693.	2.2	18
118	Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?. <i>Leukemia and Lymphoma</i> , 2011, 52, 205-213.	1.3	18
119	Isolation of Side Population Cells in B-Cell Non-Hodgkin's Lymphomas. <i>Acta Haematologica</i> , 2013, 129, 10-17.	1.4	18
120	Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	18
121	Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life. <i>Annals of Hematology</i> , 2017, 96, 739-747.	1.8	18
122	Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. <i>Cancer Science</i> , 2018, 109, 2056-2062.	3.9	18
123	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 803.	2.6	18
124	Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell Leukemia. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 382-384.	1.3	17
125	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012, 30, 368-375.	2.6	17
126	Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea. <i>Acta Haematologica</i> , 2014, 131, 18-27.	1.4	17



#	ARTICLE	IF	CITATIONS
127	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	2.6	17
128	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	17.0	17
129	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2020, 136, 2548-2556.	1.4	17
130	Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Oncotarget</i> , 2017, 8, 13782-13791.	1.8	17
131	Clonal relationships in recurrent B-cell lymphomas. <i>Oncotarget</i> , 2016, 7, 12359-12371.	1.8	17
132	Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 890-899.	1.7	17
133	Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease – Consortium for Improving Survival of Lymphoma Study. <i>Acta Haematologica</i> , 2012, 127, 100-104.	1.4	16
134	Unmet needs of non-Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with health-related quality of life. <i>Psycho-Oncology</i> , 2017, 26, 330-336.	2.3	16
135	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	1.8	16
136	Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma. <i>Cancer Science</i> , 2018, 109, 3971-3980.	3.9	16
137	A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study. <i>Scientific Reports</i> , 2019, 9, 14961.	3.3	16
138	Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis. <i>Scientific Reports</i> , 2019, 9, 7746.	3.3	16
139	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192.	3.7	16
140	Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. <i>Leukemia</i> , 2021, 35, 1356-1364.	7.2	16
141	Autocrine Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 Growth Pathway Represents a Cyclooxygenase-2-Independent Target for the Cyclooxygenase-2 Inhibitor NS-398 in Colon Cancer Cells. <i>Oncology</i> , 2005, 68, 204-211.	1.9	15
142	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. <i>Medical Oncology</i> , 2010, 27, 91-97.	2.5	15
143	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience. <i>Acta Haematologica</i> , 2010, 123, 48-54.	1.4	15
144	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. <i>Blood Research</i> , 2015, 50, 242.	1.3	15

#	ARTICLE	IF	CITATIONS
145	Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. <i>Annals of Hematology</i> , 2020, 99, 1293-1302.	1.8	15
146	Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis. <i>Journal of Cancer</i> , 2021, 12, 2825-2834.	2.5	15
147	Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study. <i>Annals of Hematology</i> , 2012, 91, 1747-1756.	1.8	14
148	Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 591-595.	1.6	14
149	Macrophage inflammatory protein 1 alpha (MIP-1 $\alpha$ ) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 310-316.	1.7	14
150	Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1341-1348.	1.3	14
151	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. <i>Journal of Cancer</i> , 2017, 8, 1018-1024.	2.5	14
152	CXCR4 can induce PI3K inhibitor resistance in ABC DLBCL. <i>Blood Cancer Journal</i> , 2018, 8, 23.	6.2	14
153	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , 2018, 53, 967-976.	2.4	14
154	Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. <i>Blood Advances</i> , 2020, 4, 868-879.	5.2	14
155	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
156	Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue. <i>Cancer Research and Treatment</i> , 2007, 39, 109.	3.0	14
157	Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 448-457.	3.0	14
158	Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors. <i>Cancer Research and Treatment</i> , 2018, 50, 204-211.	3.0	14
159	Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 617-625.	1.8	13
160	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	1.8	13
161	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	2.4	13
162	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 628807.	2.8	13

#	ARTICLE	IF	CITATIONS
163	The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. <i>Anticancer Research</i> , 2015, 35, 2465-74.	1.1	13
164	Unusual Presentation of Ewing Sarcoma in the Adrenal Gland: A Secondary Malignancy from a Survivor of Burkitt Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 676-680.	1.3	12
165	Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. <i>OncoTargets and Therapy</i> , 2014, 7, 1717.	2.0	12
166	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018, 181, 707-710.	2.5	12
167	Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 317-325.	1.3	12
168	Phase II study of Râ€“CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	12
169	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	3.3	12
170	Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 3548.	3.7	12
171	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	1.8	12
172	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
173	A Case of Non-Hodgkin`s Lymphoma in a patient with Neurofibromatosis Type 1. <i>Korean Journal of Internal Medicine</i> , 2003, 18, 202-205.	1.7	12
174	Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value?. <i>Leukemia and Lymphoma</i> , 2012, 53, 173-175.	1.3	11
175	Clinical features and outcomes of Hodgkinâ€™s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). <i>Annals of Hematology</i> , 2012, 91, 223-233.	1.8	11
176	Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. <i>Haematologica</i> , 2015, 100, e106-e109.	3.5	11
177	KIR alloreactivity based on the receptorâ€“ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. <i>Human Immunology</i> , 2015, 76, 636-643.	2.4	11
178	Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. <i>Blood Research</i> , 2016, 51, 181.	1.3	11
179	Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability. <i>Annals of Hematology</i> , 2016, 95, 581-591.	1.8	11
180	Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma. <i>Cytokine</i> , 2019, 113, 371-379.	3.2	11

#	ARTICLE	IF	CITATIONS
181	Validation of the Marginal Zone Lymphoma International Prognostic Index. <i>Annals of Hematology</i> , 2019, 98, 457-464.	1.8	11
182	99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis. <i>Medicine (United States)</i> , 2019, 98, 100-107.	1.0	11
183	Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis. <i>International Journal of Heart Failure</i> , 2020, 2, 231.	2.7	11
184	Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. <i>American Journal of Hematology</i> , 2009, 84, 826-829.	4.1	10
185	Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. <i>Annals of Hematology</i> , 2010, 89, 1011-1018.	1.8	10
186	Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2010, 28, 171-177.	2.6	10
187	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. <i>Blood Research</i> , 2014, 49, 107.	1.3	10
188	Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 865-873.	2.3	10
189	Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1427-1436.	1.8	10
190	Prognostic values of novel biomarkers in patients with AL amyloidosis. <i>Scientific Reports</i> , 2019, 9, 12200.	3.3	10
191	A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups. <i>Frontiers in Oncology</i> , 2021, 11, 696147.	2.8	10
192	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 173-181.	3.0	10
193	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. <i>Anticancer Research</i> , 2014, 34, 4299-306.	1.1	10
194	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 27-33.	2.3	9
195	A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. <i>Investigational New Drugs</i> , 2013, 31, 1514-1521.	2.6	9
196	Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients. <i>Supportive Care in Cancer</i> , 2014, 22, 2669-2675.	2.2	9
197	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
198	Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2019, 34, 579-588.	1.3	9

#	ARTICLE	IF	CITATIONS
199	Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	9
200	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP). <i>Cancer Research and Treatment</i> , 2019, 51, 164-171.	1.64	10
201	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	8.4	9
202	Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum $\beta_2$ -microglobulin Levels. <i>Cancer Research and Treatment</i> , 2021, 53, 847-856.	3.0	9
203	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 82.	2.6	9
204	Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein. <i>Cancer Research and Treatment</i> , 2014, 46, 307-311.	3.0	9
205	Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 547-555.	3.0	9
206	Stage IV marginal zone B-cell lymphoma: prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Cancer Science</i> , 2010, 101, 2443-2447.	3.9	8
207	Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?. <i>The Korean Journal of Hematology</i> , 2012, 47, 202.	0.7	8
208	A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2274-2284.	6.4	8
209	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Investigational New Drugs</i> , 2020, 38, 1472-1482.	2.6	8
210	Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. <i>Cytokine</i> , 2020, 129, 155048.	3.2	8
211	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. <i>Annals of Hematology</i> , 2020, 99, 1283-1291.	1.8	8
212	Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2021, 39, 664-673.	1.7	8
213	Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 946-956.	1.7	8
214	Clinical Outcomes and Prognostic Factors of Front-Line Autologous Stem Cell Transplantation in Patients with Extranodal NK/T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 2523-2523.	1.4	8
215	Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma: Does it have a prognostic value?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1623-1626.	1.3	7
216	A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1110-1118.	1.3	7

#	ARTICLE	IF	CITATIONS
217	Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma. <i>Acta Haematologica</i> , 2015, 133, 179-182.	1.4	7
218	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. <i>Oncotarget</i> , 2016, 7, 47127-47133.	1.8	7
219	Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. <i>Blood Cancer Journal</i> , 2017, 7, 653.	6.2	7
220	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. <i>International Journal of Hematology</i> , 2019, 110, 438-446.	1.6	7
221	Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis. <i>Annals of Laboratory Medicine</i> , 2019, 39, 430-437.	2.5	7
222	Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016. <i>Medicine (United States)</i> , 2019, 98, e17641.	1.0	7
223	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 731-740.	1.2	7
224	Primary Follicular Lymphoma in a Male Breast: A Case Report. <i>Cancer Research and Treatment</i> , 2014, 46, 104-107.	3.0	7
225	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea. <i>Blood</i> , 2009, 114, 5024-5024.	1.4	7
226	Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation. <i>Acta Haematologica</i> , 2014, 132, 226-232.	1.4	6
227	Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. <i>International Journal of Hematology</i> , 2015, 102, 678-688.	1.6	6
228	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016, 51, 193.	1.3	6
229	Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Acta Haematologica</i> , 2016, 136, 186-190.	1.4	6
230	Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. <i>Leukemia Research</i> , 2017, 57, 1-8.	0.8	6
231	Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. <i>Blood Research</i> , 2017, 52, 193.	1.3	6
232	Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. <i>Annals of Hematology</i> , 2020, 99, 223-228.	1.8	6
233	Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. <i>Scientific Reports</i> , 2020, 10, 11649.	3.3	6
234	Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. <i>Patient Education and Counseling</i> , 2020, 103, 1630-1636.	2.2	6



#	ARTICLE	IF	CITATIONS
235	Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization. <i>BMC Cancer</i> , 2020, 20, 619.	2.6	6
236	Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 669817.	2.8	6
237	Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. <i>BMC Cancer</i> , 2021, 21, 972.	2.6	6
238	Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 7289-7297.	1.9	6
239	High-Dose Cytarabine Consolidation (â€”1.5 g/m <sup>2</sup> ) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m <sup>2</sup> ) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen. <i>Blood</i> , 2013, 122, 2692-2692.	1.4	6
240	Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. <i>Oncotarget</i> , 2016, 7, 68350-68359.	1.8	6
241	Body Cavityâ€”Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1302-1312.	3.0	6
242	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 200.	6.2	6
243	Mesenchymal Stem Cells Derived from Human Chorionic Plate May Promote Hematopoietic Differentiation of the Human Embryonic Stem Cell Line SNUHES3. <i>Acta Haematologica</i> , 2006, 116, 219-222.	1.4	5
244	Waldeyerâ€™s ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). <i>International Journal of Hematology</i> , 2012, 96, 631-637.	1.6	5
245	Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 204-211.	3.0	5
246	Plerixafor use for peripheral blood stem cell mobilization in Korea. <i>Blood Research</i> , 2013, 48, 72.	1.3	5
247	Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	5
248	Spinal cord compression in multiple myeloma: a single center experience. <i>Leukemia and Lymphoma</i> , 2014, 55, 2395-2397.	1.3	5
249	A subset of CD45+/CD19 â€” cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3052-3057.	1.3	5
250	Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. <i>Annals of Laboratory Medicine</i> , 2016, 36, 209-214.	2.5	5
251	Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 995-1001.	1.3	5
252	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885.	2.6	5



#	ARTICLE	IF	CITATIONS
253	Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. <i>Annals of Hematology</i> , 2018, 97, 1851-1857.	1.8	5
254	Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping. <i>Scientific Reports</i> , 2021, 11, 5879.	3.3	5
255	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	5
256	Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4443-4443.	1.4	5
257	tipNrich: A Tip-Based N-Terminal Proteome Enrichment Method. <i>Analytical Chemistry</i> , 2021, 93, 14088-14098.	6.5	5
258	Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2022, 42, 558-565.	2.5	5
259	Lymphoma stem cells: A step toward a new therapeutic target. <i>The Korean Journal of Hematology</i> , 2011, 46, 211.	0.7	4
260	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , 2016, 95, 911-919.	1.8	4
261	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	1.3	4
262	Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 275-278.	9.2	4
263	EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 10342.	3.3	4
264	Role of 23.4Â Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. <i>Journal of Neuro-Oncology</i> , 2021, 154, 207-217.	2.9	4
265	Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis. <i>ESC Heart Failure</i> , 2021, , .	3.1	4
266	Recent advances in understanding and managing T-cell lymphoma. <i>F1000Research</i> , 2017, 6, 2123.	1.6	4
267	Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma. <i>Cancer Research and Treatment</i> , 2017, 49, 92-103.	3.0	4
268	Prognostic significance of serum Î²2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2021, , 1-7.	1.3	4
269	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. <i>Journal of Cancer</i> , 2022, 13, 1388-1397.	2.5	4
270	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. <i>Cancer Research and Treatment</i> , 2023, 55, 291-303.	3.0	4

#	ARTICLE	IF	CITATIONS
271	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
272	Phase 1/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7522-7522.	1.6	4
273	Unusual Presentation of Thymic Carcinoma : Hypertrophic Osteoarthropathy. <i>Korean Journal of Internal Medicine</i> , 2003, 18, 125-128.	1.7	3
274	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 317-320.	1.3	3
275	Dexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2196-2198.	1.3	3
276	Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea. <i>Blood Research</i> , 2015, 50, 187.	1.3	3
277	Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. <i>Blood Research</i> , 2015, 50, 160.	1.3	3
278	Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. <i>International Journal of Hematology</i> , 2015, 102, 420-425.	1.6	3
279	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	1.8	3
280	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020, 4, 5762-5771.	5.2	3
281	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. <i>Transplant International</i> , 2020, 33, 1211-1219.	1.6	3
282	Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. <i>Journal of Cancer</i> , 2021, 12, 2488-2497.	2.5	3
283	Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. <i>Scientific Reports</i> , 2021, 11, 9243.	3.3	3
284	Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 4241-4250.	1.9	3
285	Immune checkpoint inhibitors in patients with pretreated Hodgkin's lymphoma: a Korean single-center, retrospective study. <i>Blood Research</i> , 2020, 55, 85-90.	1.3	3
286	Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 307-316.	2.9	3
287	A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum $\beta$ -2-Microglobulin to PINK. <i>Cancer Research and Treatment</i> , 2023, 55, 314-324.	3.0	3
288	CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain. <i>Blood Advances</i> , 2022, 6, 6120-6130.	5.2	3

#	ARTICLE	IF	CITATIONS
289	Mantle cell lymphoma: a model for risk-adapted treatment approach. <i>Blood Research</i> , 2014, 49, 1.	1.3	2
290	Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. <i>International Forum of Allergy and Rhinology</i> , 2015, 5, 960-966.	2.8	2
291	<i>Mycobacterium abscessus</i> glossitis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1098.	9.1	2
292	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2051-2059.	2.4	2
293	Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 668-678.	1.7	2
294	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34 <sup>+</sup> cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2021, 36, 737-749.	1.3	2
295	A Case of Burkitt-Like Lymphoma With 11q Aberration With HIV Infection in East Asia and Literature Review. <i>Annals of Laboratory Medicine</i> , 2021, 41, 593-597.	2.5	2
296	Myelomatous Pleural Effusion of Multiple Myeloma: Characteristics and Outcome.. <i>Blood</i> , 2009, 114, 3874-3874.	1.4	2
297	Phase II Trial Of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (methotrexate, ifosfamide, etoposide, dexamethasone, and L-asparaginase) Chemotherapy For Patients With Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Blood</i> , 2013, 122, 3037-3037.	1.4	2
298	A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 5465-5465.	1.4	2
299	A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8023-8023.	1.6	2
300	Prevalence and Immunophenotypic Characteristics of Monoclonal B-Cell Lymphocytosis in Healthy Korean Individuals With Lymphocytosis. <i>Annals of Laboratory Medicine</i> , 2020, 40, 409-413.	2.5	2
301	Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 560-569.	1.7	2
302	Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. <i>British Journal of Haematology</i> , 2022, 196, 1117-1120.	2.5	2
303	Prognostic Significance of Ki-67 Expression in Extranodal NK/T Cell Lymphoma, Nasal Type: A Proposed Prognostic Index, KLABS Index.. <i>Blood</i> , 2006, 108, 2055-2055.	1.4	2
304	Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. <i>PLoS ONE</i> , 2018, 13, e0192656.	2.5	2
305	Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 641-648.	2.4	2
306	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2

#	ARTICLE	IF	CITATIONS
307	Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma. <i>Annals of Hematology</i> , 0, , .	1.8	2
308	Reply to K. Shimada et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e230-e230.	1.6	1
309	Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults. <i>Annals of Laboratory Medicine</i> , 2020, 40, 88-91.	2.5	1
310	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 4969-4977.	2.2	1
311	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
312	Obesity-Independent Association between Glycemic Status and the Risk of Hematologic Malignancy: A Nationwide Population-Based Longitudinal Cohort Study. <i>Cancers</i> , 2021, 13, 4760.	3.7	1
313	Detection of Extracellular Protein Kinase A (ECPKA) Autoantibody in Non-Hodgkin's Lymphoma: Its Increased Antibody Titer Decreases with a Favorable Treatment Response.. <i>Blood</i> , 2006, 108, 4621-4621.	1.4	1
314	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.. <i>Blood</i> , 2009, 114, 4902-4902.	1.4	1
315	Osteonecrosis of the Jaw in Multiple Myeloma Patients: Incidence and Characteristics in Korean Patients.. <i>Blood</i> , 2009, 114, 4956-4956.	1.4	1
316	Peripheral Blood Eosinophilia: An Unusual Presentation of Bone Marrow Involvement in a Patient with Relapsed Thyroid Papillary Carcinoma. <i>The Korean Journal of Hematology</i> , 2005, 40, 274.	0.7	1
317	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20698-e20698.	1.6	1
318	Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab. <i>Korean Journal of Medicine</i> , 2017, 92, 415-418.	0.3	1
319	Development of Lower Extremity Lymphedema Nursing Practice Protocol for Patients Following Gynecologic Cancer Treatment. <i>Asian Oncology Nursing</i> , 2018, 18, 143.	0.6	1
320	Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab. <i>Blood</i> , 2019, 134, 2227-2227.	1.4	1
321	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 194-204.	1.7	1
322	Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis. <i>Blood Research</i> , 2021, , .	1.3	1
323	Comprehensive Understanding of Gut Microbiota in Treatment Na <sup>+</sup> -ve Diffuse Large B Cell Lymphoma Patients. <i>Blood</i> , 2021, 138, 2409-2409.	1.4	1
324	Prediction of the breakthrough cancer pain using deep learning model.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24085-e24085.	1.6	0

#	ARTICLE	IF	CITATIONS
325	Does Real-time Compound Imaging Improve Evaluation of Breast Cancer Compared to Conventional Sonography?. Journal of Korean Breast Cancer Society, 2002, 5, 102.	0.1	0
326	The Cutoff Value of Serum Ferritin for the Diagnosis of Iron Deficiency in the Community-Residing Older Persons.. Blood, 2004, 104, 5291-5291.	1.4	0
327	The Effect of Telomerase Antisense for the Differentiation of Embryonic Stem Cells to Hemopoietic Stem Cells.. Blood, 2004, 104, 4201-4201.	1.4	0
328	Prediction of Survival in Patients with Non-Hodgkinâ€™s Lymphoma: Role of Tumor Necrosis Factor Ligand-Receptor and Extracellular Protein Kinase A.. Blood, 2005, 106, 4737-4737.	1.4	0
329	Treatment Outcome of Localized Extranodal NK/T Cell Lymphoma in Nasal and Upper Aerodigestive Tract: A Single Institute Experience in Korea.. Blood, 2005, 106, 2682-2682.	1.4	0
330	Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease. The Korean Journal of Hematology, 2007, 42, 335.	0.7	0
331	A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOX) for Patients with Refractory/Relapsed Aggressive Non-Hodgkinâ€™s Lymphoma.. Blood, 2007, 110, 3446-3446.	1.4	0
332	Serum B-Cell Activating Factor (BAFF) in Diffuse Large B-Cell Lymphoma: Its Prognostic Significance in the Rituximab Era.. Blood, 2007, 110, 1575-1575.	1.4	0
333	Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.. Blood, 2007, 110, 4843-4843.	1.4	0
334	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. Blood, 2008, 112, 4219-4219.	1.4	0
335	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. Blood, 2009, 114, 4661-4661.	1.4	0
336	Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?. Blood, 2010, 116, 5084-5084.	1.4	0
337	The International Prognostic Index Is a Better Predictor of Thrombotic Complications Than the Khorana Score for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Results of a Single Center Prospective Cohort Study. Blood, 2012, 120, 5095-5095.	1.4	0
338	The Clinical Significance Of Activated p-AKT Expression In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 4315-4315.	1.4	0
339	The Distinct Stem Cell Population Derived From Chorionic Plate Of Human Placenta Which Has Differentiation Potential Into Erythroid Lineage Cells. Blood, 2013, 122, 4843-4843.	1.4	0
340	Neutropenic and Non-Neutropenic Fever In Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-CHOP Chemotherapy. Blood, 2013, 122, 5103-5103.	1.4	0
341	Extranodal NK/T-Cell Lymphoma, Nasal Type. , 2014, , 121-131.		0
342	Clinical Relevance of CD45+/CD19- Stem-like Tumor Cells in Patients with Mantle Cell Lymphoma: A Single Center Experience. Blood, 2014, 124, 1622-1622.	1.4	0

#	ARTICLE	IF	CITATIONS
343	Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2015, 126, 3942-3942.	1.4	0
344	Dyadic Concordance of Sexuality Among Hematopoietic Stem Cell Transplantation Patients and Their Partners. Blood, 2015, 126, 4349-4349.	1.4	0
345	Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies. Blood, 2015, 126, 4889-4889.	1.4	0
346	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. Blood, 2015, 126, 1904-1904.	1.4	0
347	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. Blood, 2015, 126, 5160-5160.	1.4	0
348	Clinical utility of comprehensive approach to detect genetic abnormalities in multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8034-8034.	1.6	0
349	Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group. Blood, 2016, 128, 4650-4650.	1.4	0
350	Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy. Blood, 2016, 128, 3041-3041.	1.4	0
351	Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era. Blood, 2019, 134, 4002-4002.	1.4	0
352	The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type. Blood, 2019, 134, 2847-2847.	1.4	0
353	Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center. Blood, 2019, 134, 5585-5585.	1.4	0
354	Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis. Archives of Medical Science, 0, , .	0.9	0
355	Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-7.	3.0	0